

Lucas	Palazzo	Stefanik
Luetkemeyer	Palmer	Steil
Mace	Pence	Steube
Malliotakis	Perry	Stewart
Mann	Pfleger	Taylor
Massie	Posey	Tenney
Mast	Reed	Thompson (PA)
McCarthy	Reschenthaler	Tiffany
McCauley	Rice (SC)	Timmons
McClain	Rodgers (WA)	Turner
McClintock	Rogers (AL)	Upton
McHenry	Rogers (KY)	Valadao
McKinley	Rose	Van Drew
Meijer	Rosendale	Van Dwyne
Meuser	Rouzer	Wagner
Miller (IL)	Roy	Walberg
Miller (WV)	Rutherford	Walorski
Miller-Meeks	Salazar	Waltz
Moolenaar	Scalise	Weber (TX)
Mooney	Schweikert	Webster (FL)
Moore (UT)	Sessions	Wenstrup
Mullin	Simpson	Westerman
Murphy (NC)	Smith (MO)	Williams (TX)
Nehls	Smith (NE)	Wilson (SC)
Newhouse	Smith (NJ)	Wittman
Norman	Smucker	Womack
Nunes	Spartz	Young
Oberholte	Stauber	Zeldin
Owens	Steel	

NOT VOTING—7

Blumenauer	Gohmert	Scott, Austin
Burchett	Jackson	
Emmer	Moore (AL)	

□ 1417

So the resolution was agreed to.

The result of the vote was announced as above recorded.

A motion to reconsider was laid on the table.

Stated against:

Mr. EMMER. Mr. Speaker, I was unavoidably detained. Had I been present, I would have voted “nay” on rollcall No. 176.

Mr. AUSTIN SCOTT of Georgia. Mr. Speaker, I was unavoidably detained. Had I been present, I would have voted “nay” on rollcall No. 176.

MEMBERS RECORDED PURSUANT TO HOUSE RESOLUTION 8, 117TH CONGRESS

Aderholt	Kelly (IL)	Napolitano
(Moolenaar)	(Jeffries)	(Correa)
Amodei	Kirkpatrick	Pappas (Kuster)
(Balderson)	(Stanton)	Payne (Pallone)
DeFazio (Davids)	Lawson (FL)	Ruiz (Aguilar)
(KS)	(Evans)	Rush
DeSaulnier	Lieu (Beyer)	(Underwood)
(Matsui)	Lowenthal	Sewell (DelBene)
Garcia (IL)	(Beyer)	Vela (Gomez)
(Garcia (TX))	Meng (Clark)	Velázquez
Hoyer (Brown)	(MA)	(Jeffries)
Johnson (TX)	Mullin (Cole)	Wilson (FL)
(Jeffries)		(Hayes)

PROVIDING AMOUNTS FOR THE EXPENSES OF THE SELECT COMMITTEE ON ECONOMIC DISPARITY AND FAIRNESS IN GROWTH

The SPEAKER pro tempore (Mr. CUELLAR). Pursuant to section 10 of House Resolution 486, House Resolution 485 is hereby adopted.

The text of the resolution is as follows:

H. RES. 485

Resolved,

SECTION 1. AMOUNTS FOR COMMITTEE EXPENSES.

For the expenses of the Select Committee on Economic Disparity and Fairness in Growth (hereafter in this resolution referred to as the “Select Committee”), including the expenses of all staff salaries, there shall be paid, out of the applicable accounts of the House of Representatives for committee salaries and expenses, not more than \$3,500,000 for the One Hundred Seventeenth Congress.

SEC. 2. SESSION LIMITATIONS.

Of the amount specified in section 1—

(1) not more than \$1,500,000 shall be available for expenses incurred during the period beginning on the date of the adoption of this resolution and ending immediately before noon on January 3, 2022; and

(2) not more than \$2,000,000 shall be available for expenses incurred during the period beginning at noon on January 3, 2022, and ending immediately before noon on January 3, 2023.

SEC. 3. VOUCHERS.

Payments under this resolution shall be made on vouchers authorized by the Select Committee, signed by the Chairman of the Select Committee, and approved in the manner directed by the Committee on House Administration.

SEC. 4. REGULATIONS.

Amounts made available under this resolution shall be expended in accordance with regulations prescribed by the Committee on House Administration.

MOTION TO SUSPEND THE RULES AND PASS CERTAIN BILLS

Mr. MCGOVERN. Mr. Speaker, pursuant to section 11 of House Resolution 486, I move to suspend the rules and pass H.R. 482, H.R. 704, H.R. 961, H.R. 1314, H.R. 2571, H.R. 2679, H.R. 2694, H.R. 2922, H.R. 3182, H.R. 3239, H.R. 3241, H.R. 3723, H.R. 3752, H.R. 3841, S. 409, and S. 1340.

The Clerk read the title of the bills. The text of the bills are as follows:

NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2021

H.R. 482

Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

This Act may be cited as the “Newborn Screening Saves Lives Reauthorization Act of 2021”.

SEC. 2. IMPROVED NEWBORN AND CHILD SCREENING AND FOLLOW-UP FOR HERITABLE DISORDERS.

(a) PURPOSES.—Section 1109(a) of the Public Health Service Act (42 U.S.C. 300b-8(a)) is amended—

(1) in paragraph (1), by striking “enhance, improve or” and inserting “facilitate, enhance, improve, or”;

(2) by amending paragraph (3) to read as follows:

“(3) to develop, and deliver to parents, families, and patient advocacy and support groups, educational programs that—

“(A) address newborn screening counseling, testing (including newborn screening pilot studies), follow-up, treatment, specialty services, and long-term care;

“(B) assess the target audience’s current knowledge, incorporate health communications strategies, and measure impact; and

“(C) are at appropriate literacy levels;”;

and

(3) in paragraph (4)—

(A) by striking “followup” and inserting “follow-up”; and

(B) by inserting before the semicolon at the end the following: “, including re-engaging patients who have not received recommended follow-up services and supports”.

(b) APPROVAL FACTORS.—Section 1109(c) of the Public Health Service Act (42 U.S.C. 300b-8(c)) is amended—

(1) by striking “or will use” and inserting “will use”; and

(2) by inserting “, or will use amounts received under such grant to enhance capacity

and infrastructure to facilitate the adoption of,” before “the guidelines and recommendations”.

SEC. 3. ADVISORY COMMITTEE ON HERITABLE DISORDERS IN NEWBORNS AND CHILDREN.

Section 1111 of the Public Health Service Act (42 U.S.C. 300b-10) is amended—

(1) in subsection (b)—

(A) in paragraph (5), by inserting “and adopt process improvements” after “take appropriate steps”;

(B) in paragraph (7) by striking “and” at the end;

(C) by redesignating paragraph (8) as paragraph (9);

(D) by inserting after paragraph (7) the following:

“(8) develop, maintain, and publish on a publicly accessible website consumer-friendly materials detailing—

“(A) the uniform screening panel nomination process, including data requirements, standards, and the use of international data in nomination submissions; and

“(B) the process for obtaining technical assistance for submitting nominations to the uniform screening panel and detailing the instances in which the provision of technical assistance would introduce a conflict of interest for members of the Advisory Committee; and”;

(E) in paragraph (9), as redesignated—

(i) by redesignating subparagraphs (K) and (L) as subparagraphs (L) and (M), respectively; and

(ii) by inserting after subparagraph (J) the following:

“(K) the appropriate and recommended use of safe and effective genetic testing by health care professionals in newborns and children with an initial diagnosis of a disease or condition characterized by a variety of genetic causes and manifestations;”;

(2) in subsection (g)—

(A) in paragraph (1) by striking “2019” and inserting “2026”; and

(B) in paragraph (2) by striking “2019” and inserting “2026”.

SEC. 4. CLEARINGHOUSE OF NEWBORN SCREENING INFORMATION.

Section 1112(c) of the Public Health Service Act (42 U.S.C. 300b-11(c)) is amended by striking “and supplement, not supplant, existing information sharing efforts” and inserting “and complement other Federal newborn screening information sharing activities”.

SEC. 5. LABORATORY QUALITY AND SURVEILLANCE.

Section 1113 of the Public Health Service Act (42 U.S.C. 300b-12) is amended—

(1) in subsection (a)—

(A) in paragraph (1)—

(i) by striking “performance evaluation services,” and inserting “development of new screening tests,”; and

(ii) by striking “and” at the end;

(B) in paragraph (2)—

(i) by striking “performance test materials” and inserting “test performance materials”; and

(ii) by striking the period at the end and inserting “; and”;

(C) by adding at the end the following:

“(3) performance evaluation services to enhance disease detection, including the development of tools, resources, and infrastructure to improve data analysis, test result interpretation, data harmonization, and dissemination of laboratory best practices.”;

(2) in subsection (b) to read as follows:

“(b) SURVEILLANCE ACTIVITIES.—The Secretary, acting through the Director of the Centers for Disease Control and Prevention, and taking into consideration the expertise